难治性痛风药物治疗的研究进展  

Research progress of drug therapy for refractory gout

作　　者：王鹏 余玲 李果 张全波[2] 青玉凤[2] WANG Peng;YU Ling;LI Guo;ZHANG Quanbo;QING Yufeng(Department of Geriatric Medicine,Xichong County People′s Hospital,Nanchong 637000,China;Research Center for Hyperuricemia and Gout,Affiliated Hospital of North Sichuan Medical College,Nanchong 637000,China;Department of Clinical Laboratory,Xichong County People′s Hospital,Nanchong 637000,China)

机构地区：[1]西充县人民医院老年科,南充637000 [2]川北医学院附属医院高尿酸血症与痛风研究中心,南充637000 [3]西充县人民医院检验科,南充637000

出　　处：《中国临床新医学》2025年第2期230-234,共5页CHINESE JOURNAL OF NEW CLINICAL MEDICINE

基　　金：国家自然科学基金项目(编号:81974250);南充市市校科技战略合作项目(编号:20SXCXTD0002);南充市应用技术研究与开发专项项目(编号:24YFZJZC0034)。

摘　　要：难治性痛风(RG)患者往往病情重,疗效差,反复急性发作,容易出现关节破坏、功能障碍等,严重影响生活质量。近年来,对RG的临床特征及危险因素研究有了新认识,治疗药物研究也取得了新进展。该文对RG药物治疗的研究进展作一综述。Patients with refractory gout(RG)often have severe disease condition,and don′t respond well to medication.The patients are prone to recurrent acute attacks,and are more prone to joint destruction and dysfunction,which seriously affect the quality of life of the patients.In recent years,a new understanding of the clinical characteristics and risk factors of RG has been obtained,and new progress has been made in the research of therapeutic drugs.In this paper,the research progress of drug therapy for RG is reviewed.

关 键 词：难治性痛风 药物治疗 新型抗炎镇痛药物 尿酸氧化酶制剂 

分 类 号：R589.7[医药卫生—内分泌]